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ABSTRACT
The objective of this study was to investigate the relation between
the peripheral concentrations of the adrenal steroid hormones cortisol
and dehydroepiandrosterone sulfate (DHEAS) and cognitive impair-
ment and decline. A prospective study design was used. The setting
was a suburb of Rotterdam, The Netherlands. The study population
consisted of a sample of 189 healthy participants from the population-
based Rotterdam Study, aged 55–80 yr, who were invited for an
additional examination. Follow-up examinations took place 1.9 yr
after baseline, on the average. We determined fasting blood levels of
DHEAS before dexamethasone administration and of cortisol and
corticosteroid-binding globulin before and after the administration of
1 mg dexamethasone overnight. The 30-point Mini-Mental State Ex-
amination (MMSE) was used to assess cognition. The associations
with cognitive impairment (MMSE score of ,26; 6% of the sample)
and cognitive decline (drop in MMSE score of .1 point/yr; 24%) were
estimated using logistic regression, with adjustment for age, sex,
education, and depressive symptoms. An increase of 1 SD in the es-
timate of free cortisol (SD 5 30.3) was associated with cognitive im-
pairment, although not significantly [odds ratio (OR) 5 1.5; 95%
confidence interval (CI), 0.9–2.4]. A 1 SD increase in the natural
logarithm of cortisol after the administration of 1 mg dexamethasone
(SD 5 0.68) was associated with an OR for cognitive decline of 1.5 (95%
CI, 1.0–2.3). A 1 SD increase in DHEAS (SD 5 2.10 mmol/L) was
inversely, but nonsignificantly, related to cognitive impairment
(OR 5 0.5; 95% CI, 0.2–1.1) and cognitive decline (OR 5 0.6; 95% CI,
0.4–1.1). The ratio of free cortisol over DHEAS was significantly
related to cognitive impairment (OR 5 1.8; 95% CI, 1.0–3.2). This
prospective study among healthy elderly subjects suggested that
basal free cortisol levels were positively related to cognitive impair-
ment, and cortisol levels after dexamethasone treatment were related
to cognitive decline. There was an inverse, but nonsignificant, asso-
ciation between DHEAS and cognitive impairment and decline.
(J Clin Endocrinol Metab 83: 3487–3492, 1998)
CORTISOL and dehydroepiandrosterone (DHEA) areadrenal steroid hormones. In animal studies, these
hormones have been shown to have multiple effects on the
function of the hippocampus, which is involved in learning
and memory processes (1, 2). These adrenal steroids may
thus be associated with cognitive impairment, which is a
major symptom of dementia.
Hypothalamo-pituitary-adrenal (HPA) axis overactivity,
which is related to stress and possibly also to aging, leads to
increased cortisol levels (3). Sustained cortisol exposure in
rodents and primates results in damage of the hippocampus
(4). In human studies, increased cortisol levels and HPA axis
overactivity have been associated with cognitive impairment
and dementia (3, 5–11). Only a few studies have investigated
the longitudinal association between cortisol and cognitive
function. Lupien et al. (5) found a relationship between in-
creases in cortisol levels over time and cognitive impairment
in a small sample of healthy elderly. Among 194 healthy
participants of the MacArthur Field Study, an association
was observed between increasing cortisol levels and cogni-
tive decline in women, but not in men (6).
DHEA and its sulfate, DHEAS, are regarded as markers of
aging (12). In animal experiments DHEAS has been shown
to enhance neuronal and glial survival and differentiation in
culture (13, 14), and injection of DHEAS into the brains of
mice improved long term memory (13). DHEAS may act
directly on the hippocampus, as it has been shown to enhance
the magnitude of hippocampal primed burst (2) and long
term potentiation (15). There are a number of case-control
studies on the association between DHEAS and Alzheimer’s
disease; however, these yielded conflicting results (16–18). In
one prospective population-based study, there was no con-
sistent association between DHEAS and subsequent cogni-
tive function (19).
We examined the cross-sectional and longitudinal effects
of peripheral levels of the steroid hormones cortisol and
DHEAS on cognitive impairment and decline in a sample of




The Rotterdam Study is a single center prospective population-based
study (20) designed to investigate determinants of chronic disabling
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diseases in the elderly. The conduct of the study was approved by the
medical ethics committee of Erasmus University, and written consent
was obtained from all participants. All residents of Ommoord, a suburb
in Rotterdam, aged 55 yr or over, including those living in homes for the
elderly, were invited to participate. The baseline examinations started in
May 1990 and continued until June 1993. Of the 10,275 eligible subjects,
7,983 (78%) agreed to participate. During a home visit, trained inter-
viewers administered a questionnaire, covering, among other areas,
socio-demographic background, medical history, and medication use.
This was followed by 2 clinical examinations at the research center,
including neuropsychological testing. The follow-up examination
started in September 1993 and lasted until December 1994. Of the 7,215
subjects who were still alive, 6,315 (88%) agreed to participate.
For the present additional examination, a random sample (n 5 219)
was taken of participants from the Rotterdam Study, who had completed
the baseline examination in the preceding 6 months, were between 55–80
yr old, and had no history of psychiatric or endocrine diseases, including
diabetes mellitus treated with medication. There were no differences in
age, sex, or education between our sample and the other participants of
the Rotterdam Study in the same age range and without dementia or
known diabetes mellitus. The mean baseline Mini-Mental State Exam-
ination (MMSE) score was higher in our sample [28.1 (sd 5 1.6) vs. 27.6
(sd 5 1.9); P 5 0.002].
Blood measurements
Blood was obtained after an overnight fast at the research center
between 0800–0900 h and was allowed to coagulate for 30 min. Serum
was separated by centrifugation and quickly frozen in liquid nitrogen.
In addition, an overnight dexamethasone suppression test was per-
formed (21). Participants were given a tablet of 1 mg dexamethasone and
were instructed to take this at 2300 h. The next morning, at the same time
as on the previous day, a fasting blood sample was obtained in the same
manner. Measurements included cortisol and corticosteroid-binding
globulin (CBG) before and after dexamethasone, and DHEAS before
dexamethasone. CBG levels were estimated using a double antibody
RIA with murine monoclonal antibodies against human CBG and ra-
dioiodinated CBG as the tracer (Medgenix Diagnostics, Brussels, Bel-
gium). Variation coefficients for this assay were below 12%. Cortisol and
DHEAS were estimated using Coat-A-Count kits provided by Diagnos-
tic Products (Los Angeles, CA). These kits use immobilized antibodies
against the respective steroids and radioiodinated tracers. The specific-
ity of the antibodies was high. Of the endogenous steroids, 11-deoxy-
cortisol showed the highest cross-reaction in the cortisol assay (11.4%);
for the DHEAS assay, estrone sulfate had the highest cross-reactivity
(0.56%). Variation coefficients for these assays were less than 12.5% for
cortisol and less than 6.0% for DHEAS. Two measures of cortisol were
examined, i.e. total cortisol and an estimation of free circulating cortisol,
using a formula that included cortisol, CBG, and albumin concentra-
tions, according to the method of So¨dergard et al. (22) The correlation
coefficient of free cortisol with total cortisol was 0.61. Suppression of
total cortisol after dexamethasone treatment can be regarded as a mea-
sure of negative feedback sensitivity of the HPA axis to glucocorticoids.
Because the cortisol level after dexamethasone administration was not
normally distributed, we used the natural logarithm for further calcu-
lations. We also investigated the ratio of free cortisol over DHEAS,
because DHEAS may antagonize the actions of cortisol (23–25).
MMSE
Global cognitive function was tested with the Dutch version of the
30-point MMSE during the (first) visit to the research center (26). It was
administered by specially trained research assistants. The MMSE in-
cludes questions on orientation to time and place, registration, attention
and calculation, recall, language, and visual construction. This screening
test was originally created for a clinical setting (26) and is extensively
used in epidemiological studies (27). Although it tests mainly cortical
functions, these are important to daily functioning and are severely
affected in dementia. If less than 4 individual items (of 20) were not
answered by the subject, these were rated as errors (28). If a subject did
not answer 4 or more individual items, the total MMSE score was
considered missing. Cognitive impairment was defined as a score below
26 (29), and cognitive decline as a drop in the MMSE score of more than
1 point/yr (approximately .1 sd). The mean follow-up time between the
first and second MMSEs was 1.9 yr (sd 5 0.23).
Other measurements
A number of factors were considered as possible confounding vari-
ables: age, sex, and education, classified into four levels: completed
primary education; lower vocational or general education; intermediate
vocational or general education; and higher vocational training, college,
or university (Unesco, Paris, France). For all analyses on cortisol we
adjusted for symptoms of depression. Symptoms of depression were
assessed at the follow-up examination with translated versions of the
Center for Epidemiologic Studies Depression Scale (CES-D) (30) in the
first 99 participants and the Hospital Anxiety and Depression Scale
(HADS) (31) in the last 46 participants. In 44 participants, there was no
(complete) depression scale available; these subjects were significantly
older and had a lower baseline MMSE score, but the measures of cortisol
and DHEAS were not different from those in subjects with data on the
depression scale. We used the standard cut-off of 16 or above for the
CES-D (30) and a cut-off of 8 or above for the HADS (after exclusion of
the anxiety items) (31) to identify subjects with depressive symptoms.
Body mass index (weight/height2) was considered a possible confound-
ing factor, because low food intake and low body weight might induce
relative resistance to the dexamethasone suppression test, and a low
body mass index has been related to dementia (32). In the analyses of
cognitive decline, we also adjusted for the baseline MMSE score.
Statistical analysis
One subject who was using hydrocortisone and one subject who had
a greatly elevated DHEAS level (15.1 mmol/L) were excluded from the
analyses. Complete information on cognitive function at baseline was
available for 189 subjects. Follow-up data on cognitive decline were
available for 169 subjects. For the analyses of cortisol, estrogen users (n 5
2) and users of antiepileptics (n 5 4) were excluded, as these medications
can influence cortisol and/or CBG levels and sensitivity to
dexamethasone.
Differences in baseline characteristics according to cognitive impair-
ment and according to steroid hormone levels above and below the
median were tested with the Mann-Whitney test for continuous vari-
ables and the x2 test for categorical variables. Logistic regression was
used to estimate the odds ratios (OR) and 95% confidence intervals (CI)
for the risk of cognitive impairment and decline. The independent vari-
ables of interest were total cortisol, free cortisol, the natural logarithm
of cortisol after dexamethasone administration, DHEAS, and the free
cortisol/DHEAS ratio. We included confounding variables in the model.
A missing indicator variable was created for the missing values for the
depressive symptoms. We also investigated whether there was effect
modification by gender (33) by including the product term as a covariate
in the model. All tests were two sided, and P , 0.05 was considered
statistically significant. Data analyses were performed using BMDP
statistical software (BMDP Statistical Software, Inc., Los Angeles, CA).
Results
The mean age of the participants at baseline was 67.3 yr
(sd 5 5.7). Fifty percent of the sample was female. The me-
dian baseline MMSE score was 28 (range, 20–30), and 6.3%
of the subjects were cognitively impaired. The mean drop in
the MMSE per yr was 0.22 (sd 5 0.95); 24% showed a drop
in the MMSE score of more than one point per yr. There were
no differences in age, sex, or cortisol and DHEAS levels
between subjects with and subjects without complete infor-
mation on cognitive function. Compared with subjects who
attended the follow-up examination (n 5 169), those who did
not (n 5 20) were older (71.1 vs. 66.9 yr; P 5 0.002) and had
a lower median MMSE score (27 vs. 28; P 5 0.001). There were
no differences in cortisol, CBG, or DHEAS levels between
these groups.
Subjects with cognitive impairment were older, more often
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had symptoms of depression at follow-up, and had lower
DHEAS concentrations and higher ratios of cortisol to
DHEAS (Table 1). Subjects with a total cortisol level above
the median (506.5 nmol/L) had a lower body mass index
than those with a total cortisol level below the median [25.8
(sd 5 3.8) vs. 27.1 (sd 5 3.4); P 5 0.01]. Subjects with a free
cortisol concentration above the median were older and less
often female (Table 2). Participants with DHEAS levels below
the median were more often female (66% vs. 34%; P , 0.001).
Multiple logistic regression analyses showed that there
was no association between total cortisol and cognitive im-
pairment or decline after adjustment for age, sex, educational
level, and depressive symptoms at follow-up (Table 3). The
OR for the association with cognitive impairment according
to a 1 sd increase in the free cortisol level (sd 5 30.3) was 1.5
(95% CI, 0.9–2.4). CBG levels were not associated with cog-
nitive function (data not shown). The natural logarithm of
cortisol after dexamethasone treatment was associated with
a significantly increased risk of cognitive decline (adjusted
OR per sd increase 5 1.5; 95% CI, 1.0–2.3). The DHEAS level
was inversely, but not significantly, related to cognitive im-
pairment (OR 5 0.5; 95% CI, 0.2–1.1) and decline (OR 5 0.6;
95% CI, 0.4–1.1). As expected, the ratio of cortisol over
DHEAS was significantly associated with cognitive impair-
ment (OR 5 1.8; 95% CI, 1.0–3.2). Adjustment for body mass
index did not change these estimates. Exclusion of subjects
with depressive symptoms (n 5 14) essentially yielded the
same estimates, but CIs were wider because of the smaller
sample size (results not shown). There were no significant
interactions between the variables of interest and sex.
Additionally, we investigated the association with the
memory item of the MMSE (34), as cortisol and DHEAS are
believed to influence the function of the hippocampus, which
is involved in memory processes. Fifty-three percent of the
subjects scored less than three points on the recall of three
words. There was no significant association of free cortisol or
DHEAS with memory impairment (OR 5 1.0; 95% CI, 0.7–1.4
and OR 5 1.2; 95% CI, 0.9–1.7, respectively).
Discussion
In this prospective study of healthy older subjects, we
investigated the association between the peripheral concen-
trations of two adrenal steroid hormones and cognitive func-
tion. The results suggest that a high free cortisol level was
related to cognitive impairment. The cortisol level after dexa-
methasone administration, as a measure of negative feed-
back sensitivity of the HPA axis, was associated with an
increased risk of cognitive decline. DHEAS, which may an-
tagonize the actions of glucocorticoids, appeared to be in-
versely related to cognitive impairment and decline, al-
though this was not significant. The ratio of cortisol to
DHEAS was significantly related to cognitive impairment.
These associations could not be explained by differences in
age, sex, education, depressive symptoms at follow-up, or
body mass index. There was no relationship between the
adrenal hormones and the specific memory item of the
MMSE.
Methodological issues
It could be argued that selection bias may have affected the
validity of our results. Participants were healthy and rela-
TABLE 2. Characteristics according to free cortisol above and






Mean age (yr) 66.2 (5.8)d 68.4 (5.5) 0.04
Sex (% female) 59 40 0.01
Only primary education (%) 34 29 0.30




a Calculated, based on total cortisol, CBG, and albumin levels, as
described by So¨dergard (22).
b By Mann-Whitney or x2 test.
c In total, six subjects were excluded because they were using
estrogens or antiepileptics.
d The SD is in parentheses.






Mean age (yr) 67.1 (5.7)c 71.3 (4.0) 0.01
Sex (% female) 50 58 0.56
Only primary education (%) 32 42 0.72
Body mass index (kg/m2) 26.4 (3.7) 26.2 (3.7) 0.86
Depressive symptoms at follow-up (%) 9 29 0.08
Mean cortisol (nmol/L)d 512 (134) 544 (142) 0.45
Mean free cortisol (nmol/L)d,e 31.7 (29.2) 48.1 (42.3) 0.16
Mean logarithm of cortisol after dexamethasone (nmol/L)d 3.12 (0.68) 3.32 (0.61) 0.29
Mean dehydroepiandrosterone sulfate (mmol/L) 3.36 (2.09) 2.25 (2.00) 0.03
Mean free cortisol/dehydroepiandrosterone sulfate ratio (nmol/mmol)d 13.6 (17.8) 53.1 (98.8) 0.01
CBG, Corticosteroid-binding globulin.
a Defined as a Mini-Mental State Examination score of less than 26 at baseline.
b By Mann-Whitney or x2 test.
c The SD is in parentheses.
d Six subjects were excluded because they were using estrogens or antiepileptics.
e Calculated, based on total cortisol, CBG, and albumin levels, as described by So¨dergard (22).
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tively young, and follow-up duration was short, leading, on
the average, to only a small drop in the MMSE score. Com-
bined with the small sample size, this would only impede the
detection of a significant modest association. Furthermore,
the 20 subjects in our sample without a MMSE score at
follow-up (due to death or nonresponse) had a significantly
lower baseline MMSE score and were older than subjects
who were not lost to follow-up, but there were no differences
in cortisol or DHEAS levels, making selective loss to
follow-up less likely.
The MMSE was used to assess cognitive function. Al-
though the MMSE is developed as a global clinical screening
test, it is a valid and reliable indicator of cognitive impair-
ment, with a test-retest reliability generally between 0.80–
0.95 (35). The MMSE was not originally created to measure
cognitive decline and may be less sensitive to small changes
in cognitive function. However, the reliability of the change
in the MMSE after 1 yr or more in patients with dementia was
0.74, which is reasonable (36).
Another methodological issue is that we may not have
adequately adjusted for depression. Depression is strongly
associated with cognitive impairment (37) and also with
increased cortisol levels and diminished suppression of cor-
tisol after dexamethasone treatment (38). Thus, depression is
potentially an important confounder or intermediate. The
use of two different questionnaires might not have been
optimal. The CES-D was designed for epidemiologic re-
search, whereas the HADS was designed for a clinical setting.
Both have been validated, but the CES-D is probably more
reliable, especially in this setting (30). Furthermore, we ad-
justed for symptoms of depression at follow-up and not at
baseline. Thus, there may be residual confounding in our
results for cognitive impairment, but less in our results for
cognitive decline.
Cortisol and HPA axis overactivity
Our results confirm the findings of the few prospective
studies that have investigated the association between cor-
tisol and cognition (5, 6). A prospective study among 19
healthy elderly subjects showed a relationship between in-
creases in basal cortisol levels over time and 2 out of 17
cognitive measures, i.e. explicit memory and selective atten-
tion (5). Although the researchers used a conservative test for
significance, they did not adjust for age or other possible
confounders. Among 194 healthy elderly participants from
the MacArthur Field Study, an association was observed
between a rise in cortisol levels and a decline in memory
performance, but only in women (6). No associations were
found with abstraction and spatial ability.
It has been shown that HPA axis overactivity is more
frequent among patients with Alzheimer’s disease (10). Also,
in early dementia, a decreased sensitivity to glucocorticoid
feedback, using low doses of dexamethasone, has been
shown. (11) In addition, cortisol has been associated with
severity of dementia and cognitive decline in demented pa-
tients (8, 9). Furthermore, patients with Cushing’s syndrome
more often present with cognitive impairment (39). Finally,
one of the side-effects of treatment with synthetic cortico-
steroids is cognitive deterioration (40).
The relation between cortisol and cognitive function may
be due to different effects of cortisol on the hippocampus. In
experimental animal studies, administration of corticoste-
rone led to a decrease in the number of pyramidal cells in the
hippocampus (4), soma shrinkage (41), and a reduction in the
number and length of dendritic branches (42). In patients
with Alzheimer’s disease and Cushing’s syndrome, higher
cortisol levels were associated with lower hippocampal vol-
umes (43, 44). Therefore, stress-induced HPA axis overac-
tivity and increased cortisol levels may cause hippocampal
damage and, subsequently, cognitive decline. On the other
hand, hippocampal damage, i.e. as a result of Alzheimer
pathology, may lead to HPA axis overactivity and increased
cortisol levels, because hippocampal neurons are involved in
the negative feedback of glucocorticoid secretion. This is
described as the glucocorticoid cascade of aging (45). Of
course, both sequences of events may also proceed at the
same time.
DHEAS
There has been one previous prospective population-
based study that investigated the relationship between
DHEAS and subsequent cognitive impairment, in which no
consistent association was found (19). The follow-up dura-
tion was quite long (16 yr), and subjects with lower DHEAS
levels at baseline had a higher mortality, suggesting that
there may have been selective survival bias. There have been
TABLE 3. Adjusted odds ratios (95% confidence intervals) for the risk of cognitive impairment and decline according to a 1 SD increase in







Total cortisol (nmol/l)b 140.1 1.2 (0.6–2.3) 0.9 (0.6–1.4)
Free cortisol (nmol/l)b,c 30.3 1.5 (0.9–2.4) 0.9 (0.6–1.4)
Cortisol after dexamethasone (nmol/L)b,d 0.68 1.1 (0.6–1.9) 1.5 (1.0–2.3)
Dehydroepiandrosterone sulfate (mmol/L) 2.10 0.5 (0.2–1.1) 0.6 (0.4–1.1)
Free cortisol/dehydroepiandrosterone sulfate ratio (nmol/mmol)b 31.5 1.8 (1.0–3.2) 0.9 (0.5–1.6)
Odds ratio was adjusted for age, sex, education, and symptoms of depression (and baseline Mini-Mental State Examination score in the
analyses of cognitive decline).
a Cognitive impairment: Mini-Mental State Examination score of less than 26 at baseline; cognitive decline: drop in the Mini-Mental State
Examination score of more than one point per yr.
b Six subjects were excluded because they were using estrogens or antiepileptics.
c Calculated, based on total cortisol, CBG, and albumin levels, as described by So¨dergard (22).
d After logarithmic transformation.
3490 KALMIJN ET AL. JCE & M • 1998
Vol 83 • No 10
 at Medical Library Erasmus MC on December 11, 2006 jcem.endojournals.orgDownloaded from 
a number of case-control studies on DHEAS levels and Alz-
heimer’s disease. Some found that Alzheimer’s disease pa-
tients had lower DHEAS levels than controls (16, 46), but this
could not be confirmed by others (17, 18). These studies were
mostly based on small numbers of patients and controls,
thereby increasing the possibility of false negative results. A
small pilot study among patients with major depression
showed improvement of selective memory functions after
DHEA administration (47).
Serum levels of DHEAS are the highest of all steroids in
humans. Cerebrospinal fluid levels of DHEA and DHEAS
correlated significantly with peripheral concentrations (48).
There are a number of plausible mechanisms for an associ-
ation between DHEAS and cognitive function. Animal ex-
periments showed that DHEAS can enhance neuronal and
glial survival and differentiation in culture (13, 14), perhaps
because DHEAS acts as a g-aminobutyric acid antagonist
(49). Furthermore, DHEAS can improve memory in mice
(13), which may be due to a direct effect of DHEAS on
hippocampal neurons, through enhancement of the magni-
tude of the hippocampal primed burst (2) and long term
potentiation (15) in rats. Another explanation for the asso-
ciation with cognition may be that DHEA can be transformed
into estrogens in peripheral tissues. (50) The risk of Alzhei-
mer’s disease has been shown to be reduced in women using
estrogen compared with those who did not (51). Further-
more, DHEA may act as a glucocorticoid antagonist, as de-
scribed for a number of systems (23–25). Therefore, a high
ratio of cortisol over DHEAS may especially lead to hip-
pocampal damage (15) and thus to cognitive impairment.
Indeed, the present study showed a significant association
between the cortisol/DHEAS ratio and cognitive impair-
ment. Finally, DHEAS may be regarded as a marker of gen-
eral health status and could therefore be related to cognitive
function.
Conclusion
In conclusion, this small prospective study in healthy older
subjects indicates that there may be an association between
adrenal steroid hormones and cognitive function. Free cor-
tisol appeared to be associated with cognitive impairment,
and cortisol after dexamethasone treatment increased the
risk of cognitive decline. DHEAS was inversely, but not
significantly, associated with cognitive impairment and de-
cline. However, these results are preliminary, and larger
follow-up studies of longer duration are needed to verify
these findings. It remains unclear whether the observed cog-
nitive impairment and decline are the direct result of the
altered levels of the peripheral steroids or vice versa, or if
another factor influences both adrenal steroid biosynthesis
and the processes leading to reduced cognitive function.
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